Free Trial
NASDAQ:CYTO

Altamira Therapeutics (CYTO) Stock Price, News & Analysis

Altamira Therapeutics logo
$0.48
0.00 (-0.79%)
(As of 03:30 PM ET)

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Key Stats

Today's Range
$0.47
$0.50
50-Day Range
$0.48
$0.96
52-Week Range
$0.45
$17.20
Volume
13,779 shs
Average Volume
776,715 shs
Market Capitalization
$1.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Altamira Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
34th Percentile Overall Score

CYTO MarketRank™: 

Altamira Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Altamira Therapeutics are expected to grow in the coming year, from ($2.65) to ($1.17) per share.

  • Price to Book Value per Share Ratio

    Altamira Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.31% of the float of Altamira Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Altamira Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Altamira Therapeutics has recently decreased by 50.85%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Altamira Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Altamira Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.31% of the float of Altamira Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Altamira Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Altamira Therapeutics has recently decreased by 50.85%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Altamira Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Altamira Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.03% of the stock of Altamira Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.91% of the stock of Altamira Therapeutics is held by institutions.

  • Read more about Altamira Therapeutics' insider trading history.
Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTO Stock News Headlines

Altamira Therapeutics Provides Update on Nasdaq Listing
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
See More Headlines

CYTO Stock Analysis - Frequently Asked Questions

Altamira Therapeutics' stock was trading at $3.48 at the beginning of the year. Since then, CYTO stock has decreased by 85.7% and is now trading at $0.4981.
View the best growth stocks for 2024 here
.

Shares of Altamira Therapeutics reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO).

Company Calendar

Today
11/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTO
Employees
20
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$4.56 per share

Miscellaneous

Free Float
2,958,000
Market Cap
$1.65 million
Optionable
Not Optionable
Beta
1.79
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CYTO) was last updated on 11/1/2024 by MarketBeat.com Staff
From Our Partners